Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Design Therapeutics (DSGN)
NASDAQ:DSGN
Design Therapeutics (DSGN) Stock Price & Analysis
69 Followers
DSGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.94 - $8.47
Previous Close$3.72
Volume136.65K
Average Volume (3M)265.54K
Market Cap
$210.16M
Enterprise Value-$78.26M
Total Cash (Recent Filing)$290.94M
Total Debt (Recent Filing)$2.52M
Price to Earnings (P/E)-3.1
Beta1.76
Next Earnings
Aug 05, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding56,494,271
10 Day Avg. Volume170,866
30 Day Avg. Volume265,535
Standard Deviation0.22
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.76
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.31
Forecast
1Y Price Target
$4.75Price Target Upside30.14% Upside
Rating ConsensusHold
Number of Analyst Covering4
Design Therapeutics News
PremiumPre-Earnings
Is DSGN a Buy, Before Earnings?
PremiumCompany Announcements
Design Therapeutics, Inc.: Navigating Liquidity Risks Amidst Bank Failures
Ownership Overview
57.68% Insiders
8.12% Mutual Funds
6.97% Other Institutional Investors
27.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DSGN FAQ
What was Design Therapeutics’s price range in the past 12 months?
Design Therapeutics lowest stock price was $1.94 and its highest was $8.47 in the past 12 months.
What is Design Therapeutics’s market cap?
Currently, no data Available
When is Design Therapeutics’s upcoming earnings report date?
Design Therapeutics’s upcoming earnings report date is Aug 05, 2024 which is in 89 days.
How were Design Therapeutics’s earnings last quarter?
Currently, no data Available
Is Design Therapeutics overvalued?
According to Wall Street analysts Design Therapeutics’s price is currently Undervalued.
Does Design Therapeutics pay dividends?
Design Therapeutics does not currently pay dividends.
What is Design Therapeutics’s EPS estimate?
Design Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Design Therapeutics have?
Design Therapeutics has 56,494,270 shares outstanding.
What happened to Design Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Design Therapeutics?
Among the largest hedge funds holding Design Therapeutics’s share is Baker Bros Advisors LP. It holds Design Therapeutics’s shares valued at 4M.
---
Design Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.75 (30.14% Upside)
$4.75 (30.14% Upside)
Hedge Fund Trend
Increased
By 719.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $104.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.26%
12-Months-Change
Fundamentals
Return on Equity
-22.10%
Trailing 12-Months
Asset Growth
-15.09%
Trailing 12-Months
Company Description
Design Therapeutics
Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.
---
DSGN Earnings Call
Q4 2024
0:00 / 0:00
---
DSGN Stock 12 Months Forecast
Average Price Target
$4.75
▲(30.14% Upside)
Technical Analysis
Kura Oncology
―
Assembly Biosciences
―
Ultragenyx Pharmaceutical
―
Sangamo Biosciences
―
---